IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MEDER et al.

Appl. No.: (to be assigned; U.S. National

Phase of PCT/EP2003/011799)

Int'l Filing Date: October 24, 2003

For: Human Chondroosteomodulin (TIG2), Production, and Use for the Treatment

or Diagnosis of Bone Diseases, Cartilage Diseases, Obesity, Inflammatory Diseases, and Skin

Diseases

Confirmation No.: (to be assigned)

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 2388.0010000/SRL/BLS

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Bryan L. Skelton

Agent for Applicants Registration No. 50,893

Date: April 29, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 393161_1.DOC